Industry Overview

China pharmaceutical contract manufacturing market was valued at $33.9 billion in 2025 and is projected to reach $90.8 billion by 2035, growing at a CAGR of 10.4% during the forecast period (2026–2035). The China pharmaceutical contract manufacturing market is expanding as pharmaceutical companies increasingly rely on external partners to support large-scale and regulated drug production. Manufacturers in China have strengthened their operational capabilities to meet the stringent quality and compliance expectations of international markets. Competitive production economics, combined with improved process reliability, have encouraged long-term outsourcing arrangements. Growing demand for a consistent supply of active pharmaceutical ingredients and finished formulations has further supported market growth. In addition, sustained capital investment in manufacturing facilities has enhanced production efficiency and scalability. Together, these factors are contributing to the steady development of the contract manufacturing landscape in China.

Market Dynamics

Shift Toward High-Value and Complex Drug Manufacturing

China’s pharmaceutical contract manufacturing market is increasingly moving beyond basic generics toward high-value and complex drug production, including APIs, biologics, and specialty formulations. Contract manufacturers are investing in advanced technologies such as high-potency API handling, sterile manufacturing, and biologics scale-up capabilities. This shift is driven by growing demand from global pharmaceutical companies seeking cost-effective yet technically sophisticated partners. Regulatory upgrades aligned with international standards have further enabled Chinese CMOs to participate in complex, export-oriented manufacturing. As a result, revenue contribution from value-added manufacturing services is steadily increasing.

Rising Integration with Global Supply Chains

China is strengthening its position as a key node in global pharmaceutical supply chains through contract manufacturing partnerships. International pharma companies are diversifying sourcing strategies and increasingly relying on Chinese CMOs for both API and finished dosage manufacturing. Investments in quality systems, compliance with US FDA and EMA requirements, and capacity expansion are supporting this integration. At the same time, Chinese contract manufacturers are forming long-term agreements to ensure supply security and cost stability. This trend is reinforcing China’s role as a strategic manufacturing hub rather than a purely low-cost supplier.

Market Segmentation

• Based on the manufacturing process type, the market is segmented into sterile manufacturing and non-sterile manufacturing.
• Based on the product type, the market is segmented into OTC, API, finished dosage formulation, and others.
• Based on the route of administration, the market is segmented into oral, inhaled, parenteral, and others.
• Based on the service, the market is segmented into R&D, manufacturing, and non-clinical.

Non-Sterile Manufacturing Segment to Lead the Market with the Largest Share

The growth of China’s pharmaceutical contract manufacturing market is closely linked to the expansion of non-sterile manufacturing capabilities. Contract manufacturers are increasingly handling large volumes of solid oral dosage forms, liquids, and semi-solid products for domestic and export markets. These manufacturing activities benefit from streamlined production processes and comparatively lower operational complexity. Consistent demand for chronic disease medications has further supported capacity utilization in non-sterile facilities. Improved compliance with international quality standards has increased client confidence. As a result, non-sterile manufacturing continues to be a key contributor to market expansion.

Manufacturing: A Key Segment in Market Growth

The China pharmaceutical contract manufacturing market is growing as manufacturers strengthen their core production infrastructure and technical execution. Expanded manufacturing capacity has enabled contract partners to support both large-scale and customized production requirements. Operational efficiency and process standardization have improved delivery timelines and cost control. Manufacturers are also optimizing production workflows to handle diverse product portfolios. These advancements have enhanced reliability across multiple therapeutic segments. Consequently, manufacturing capability development remains a central factor supporting sustained market growth.

Market Players Outlook

The major companies operating in the China pharmaceutical contract manufacturing market include Apeloa Pharmaceutical Co., Ltd., Asymchem Laboratories (Tianjin) Co., Ltd., Pharmaron (Beijing) Co., Ltd., WuXi AppTec Co., Ltd., WuXi Biologics Cayman Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In November 2025, WuXi XDC Cayman Inc. (WuXi XDC), a global contract research, development, and manufacturing organisation focused on the bioconjugate sector, entered into a Memorandum of Understanding with Standard Chartered Bank (China) Limited to establish a comprehensive strategic partnership. The collaboration is intended to support WuXi XDC’s global business development, domestic and international strategic planning, and the broader bioconjugate ecosystem.

• In August 2025, Fosun Pharma announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc. (Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in the Chinese Mainland, Hong Kong SAR, and Macau SAR.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the China pharmaceutical contract manufacturing market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.